Demonstrated 86% sensitivity even in stage 1-2 바카라 카지노 cancer patients
[by Yu, Suin] Gencurix announced on April 1 the release of clinical results for 'HEPA eDX,' an early diagnosis test for liver cancer, along with preliminary findings from a study investigating its effectiveness in monitoring recurrence after treatment.
According to the company, the study findings were presented by Professor Park Soon-jae of Inje University Haeundae Paik Hospital at 'HBP Surgery Week 2025,' the largest international academic conference specializing in biliary tract and pancreas diseases. 바카라 카지노 eDX is a digital PCR-based molecular diagnostic test designed for early detection of liver cancer by identifying methylation biomarkers in 'circulating tumor DNA (ctDNA)' present in the blood.
The 바카라 카지노 trial was conducted on a total of 160 participants, including liver cancer patients, high-risk groups for chronic liver disease, and healthy individuals. The study was jointly led by Professor Wang Hee-jung and Professor Park Soon-jae's research team from Inje University Haeundae Paik Hospital. The presentation provided a comprehensive overview of the study process, covering biomarker discovery, validation using cell lines and tissue samples, and 바카라 카지노 blood sample analysis.
The study results indicated that 바카라 카지노 eDX, when used independently, achieved a sensitivity of 77% and a specificity of 92%. Notably, when combined with serum alpha-fetoprotein (AFP) testing, sensitivity increased to 92% while maintaining the same level of specificity. Furthermore, the test demonstrated strong early diagnosis performance, achieving a sensitivity of 86% in patients with stage 1-2 liver cancer.
In addition to its mechanism of early diagnosis, Gencurix also presented follow-up research on using HEPA eDX for monitoring recurrence after treatment. The research team conducted regular post-treatment blood collection, performed HEPA eDX testing, and tracked recurrence through imaging comparisons. The company reported that the study demonstrated a correlation between treatment response and recurrence, suggesting the potential for future 바카라 카지노 applications.
“Methylation biomarkers can serve as effective tools for evaluating treatment response or predicting recurrence, as they sensitively reflect a patient’s disease status,” expressed Han Jin-il, Director of Gencurix R&D Department. “We will continue conducting follow-up research to facilitate the 바카라 카지노 application of this technology in the future.”
“Liver cancer is particularly challenging to detect in its early stages and is associated with a high recurrence rate, posing significant 바카라 카지노 challenges,” stated Professor Wang Hee-jung of Inje University Haeundae Paik Hospital. “HEPA eDX has the potential to be widely utilized not only for early diagnosis but also for monitoring patients after treatment,” he added.